EKF Diagnostics Holdings plc (AIM:EKF)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 107.70M -22.1% |
| Revenue (ttm) | 51.56M +2.7% |
| Net Income | 2.12M -66.0% |
| EPS | 0.00 -65.8% |
| Shares Out | 428.24M |
| PE Ratio | 53.52 |
| Forward PE | 15.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 78,794 |
| Open | 25.60 |
| Previous Close | 25.15 |
| Day's Range | 24.90 - 25.60 |
| 52-Week Range | 21.80 - 32.00 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 34.67 (+37.77%) |
| Earnings Date | Sep 15, 2026 |
About EKF Diagnostics Holdings
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point... [Read more]
Financial Performance
In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for EKF stock is "Strong Buy." The 12-month stock price target is 35p, which is an increase of 37.77% from the latest price.
News
EKF Diagnostics Holdings Earnings release: H1 2026
EKF Diagnostics Holdings released its H1 2026 earnings on July 30, 2026, summarizing the period's financial results.
EKF Diagnostics Holdings Earnings Call Transcript: H2 2025
Revenue rose 3% to GBP 51.6m with gross margin up to 51% and EBITDA at GBP 12.4m. Strategic execution in 2025 included portfolio simplification, strong growth in LATAM and BHB, and a GBP 5m share buyback. Outlook targets operational excellence, new product launches, and continued expansion.
EKF Diagnostics Holdings Annual report: H2 2025
EKF Diagnostics Holdings has published its H2 2025 annual report on March 24, 2026.
EKF Diagnostics Holdings Slides: H2 2025
EKF Diagnostics Holdings has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.
EKF Diagnostics Holdings Annual report: H2 2025
EKF Diagnostics Holdings has published its H2 2025 annual report on March 24, 2026.
EKF Diagnostics Holdings Earnings release: Q4 2025
EKF Diagnostics Holdings released its Q4 2025 earnings on January 27, 2026, summarizing the period's financial results.
EKF Diagnostics Holdings Earnings Call Transcript: H1 2025
Revenue and profit remained stable year-over-year, with gross margin improving to 50% and EBITDA up 7.4%. Strategic investments in production and Life Sciences, new contracts in growth markets, and a continued share buyback support long-term growth targets.
EKF Diagnostics Holdings Quarterly report: H1 2025
EKF Diagnostics Holdings has published its H1 2025 quarterly earnings report on September 16, 2025.
EKF Diagnostics Holdings Slides: H1 2025
EKF Diagnostics Holdings has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 16, 2025.